© 2018 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
In tumors with missing or mutated BRCA genes, PARP inhibitors plus other drugs have worked well—but the cancer often becomes drug-resistant.
Rubraca shrank tumors and lowered PSA levels in men with advanced prostate cancer.
PARP inhibitor demonstrates unprecedented improvement in progression-free survival.
Small Phase I trial saw an increased survival rate in people with locally advanced head and neck cancer and a history of heavy smoking.
Whole-genome analysis of aggressive disease offers insights into possible personalized therapies
New treatment options are available for those with breast cancer that has metastasized.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.
